Western blotting showed that cleaved PARP was increased by the downregulation of RBM22 in HCT116 and SUIT-2 cells but not OE33 cells, suggesting that RBM22 inhibited apoptosis, thereby promoting the progression of colorectal and pancreatic cancer. Here, RBM22 is linked to familial pancreatic carcinoma.